208 related articles for article (PubMed ID: 16315127)
21. Noninvasive testing for colorectal cancer: a review.
Ouyang DL; Chen JJ; Getzenberg RH; Schoen RE
Am J Gastroenterol; 2005 Jun; 100(6):1393-403. PubMed ID: 15929776
[TBL] [Abstract][Full Text] [Related]
22. A new fecal calprotectin test for colorectal neoplasia. Clinical results and comparison with previous method.
Johne B; Kronborg O; Tøn HI; Kristinsson J; Fuglerud P
Scand J Gastroenterol; 2001 Mar; 36(3):291-6. PubMed ID: 11305517
[TBL] [Abstract][Full Text] [Related]
23. Early Detection of Colorectal Cancer: a Multi-Center Pre-Clinical Case Cohort Study for Validation of a Combined DNA Stool Test.
Dollinger MM; Behl S; Fleig WE
Clin Lab; 2018 Oct; 64(10):1719-1730. PubMed ID: 30336540
[TBL] [Abstract][Full Text] [Related]
24. Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer.
Mulder SA; van Leerdam ME; van Vuuren AJ; Francke J; van Toorenenbergen AW; Kuipers EJ; Ouwendijk RJ
Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):878-82. PubMed ID: 17873612
[TBL] [Abstract][Full Text] [Related]
25. Many participants in fecal occult blood test population screening have a higher-than-average risk for colorectal cancer.
Worthley DL; Smith A; Bampton PA; Cole SR; Young GP
Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1079-83. PubMed ID: 16957514
[TBL] [Abstract][Full Text] [Related]
26. Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia.
Limburg PJ; Devens ME; Harrington JJ; Diehl NN; Mahoney DW; Ahlquist DA
Am J Gastroenterol; 2003 Oct; 98(10):2299-305. PubMed ID: 14572583
[TBL] [Abstract][Full Text] [Related]
27. [Pilot study on M2-PK-- a new non-invasive parameter for early diagnosis of colorectal carcinoma].
Ivanova A; Iarŭmov N; Toshev S; Adzharov D; Krŭstev Z; Angelov K; Sokolov M; Gribnev P
Khirurgiia (Sofiia); 2007; (6):5-7. PubMed ID: 18622373
[TBL] [Abstract][Full Text] [Related]
28. [Clinical significance of blood and fecal tumor M2-pyruvate kinase expression in patients with colorectal cancer].
Li Y; Wang JJ
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Dec; 31(12):2087-9. PubMed ID: 22200720
[TBL] [Abstract][Full Text] [Related]
29. [Faecal pyruvate kinase type M2--a valid screening parameter for colorectal cancer? Preliminary results from a multicenter comparative study].
Naumann M; Schaum B; Oremek GM; Hanisch E; Rösch W; Mössner J; Caspary WF; Stein J
Dtsch Med Wochenschr; 2004 Aug; 129(34-35):1806-7. PubMed ID: 15314744
[No Abstract] [Full Text] [Related]
30. The Usefulness of a Novel Screening Kit for Colorectal Cancer Using the Immunochromatographic Fecal Tumor M2 Pyruvate Kinase Test.
Kim YC; Kim JH; Cheung DY; Kim TH; Jun EJ; Oh JW; Kim CW; Chung WC; Kim BW; Kim SS; Kim JI; Park SH; Kim JK
Gut Liver; 2015 Sep; 9(5):641-8. PubMed ID: 25473070
[TBL] [Abstract][Full Text] [Related]
31. Quantitative detection of tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases.
Schneider J; Morr H; Velcovsky HG; Weisse G; Eigenbrodt E
Cancer Detect Prev; 2000; 24(6):531-5. PubMed ID: 11198266
[TBL] [Abstract][Full Text] [Related]
32. Stool test for colorectal cancer screening: what is going on?
Bonanno E; Rulli F; Galatà G; Pucci S; Sesti F; Farinon AM; Spagnoli LG
Surg Oncol; 2007 Dec; 16 Suppl 1():S43-5. PubMed ID: 18055195
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia.
Tsoi KK; Ng SS; Leung MC; Sung JJ
Aliment Pharmacol Ther; 2008 Aug; 28(3):353-63. PubMed ID: 18638075
[TBL] [Abstract][Full Text] [Related]
34. The evolution to stool DNA testing for colorectal cancer.
Tagore KS; Levin TR; Lawson MJ
Aliment Pharmacol Ther; 2004 Jun; 19(12):1225-33. PubMed ID: 15191503
[TBL] [Abstract][Full Text] [Related]
35. The tumor marker tumor M2-PK: an application in the diagnosis of gastrointestinal cancer.
Schulze G
Anticancer Res; 2000; 20(6D):4961-4. PubMed ID: 11326647
[TBL] [Abstract][Full Text] [Related]
36. Improved sensitivity in the diagnosis of gastro-intestinal tumors by fuzzy logic-based tumor marker profiles including the tumor M2-PK.
Schneider J; Bitterlich N; Schulze G
Anticancer Res; 2005; 25(3A):1507-15. PubMed ID: 16033052
[TBL] [Abstract][Full Text] [Related]
37. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
[TBL] [Abstract][Full Text] [Related]
38. Tumor M2-pyruvate kinase as tumor marker in exocrine pancreatic cancer a meta-analysis.
Kumar Y; Gurusamy K; Pamecha V; Davidson BR
Pancreas; 2007 Aug; 35(2):114-9. PubMed ID: 17632316
[TBL] [Abstract][Full Text] [Related]
39. Improved fecal DNA test for colorectal cancer screening.
Itzkowitz SH; Jandorf L; Brand R; Rabeneck L; Schroy PC; Sontag S; Johnson D; Skoletsky J; Durkee K; Markowitz S; Shuber A
Clin Gastroenterol Hepatol; 2007 Jan; 5(1):111-7. PubMed ID: 17161655
[TBL] [Abstract][Full Text] [Related]
40. Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer.
Schneider J; Schulze G
Anticancer Res; 2003; 23(6D):5089-93. PubMed ID: 14981971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
